Express News | Silence Therapeutics - From Time to Time, Co or Any Selling Shareholder May Offer and Sell Ordinary Shares
Express News | Silence Therapeutics PLC Files for Stock Shelf; Size Not Disclosed - SEC Filing
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Silence Therapeutics Insider Ups Holding During Year
Jefferies Initiates Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $40
Jefferies analyst Kelly Shi initiates coverage on $Silence Therapeutics(SLN.US)$ with a buy rating, and sets the target price at $40.According to TipRanks data, the analyst has a success rate of 42.3%
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
H.C. Wainwright analyst Patrick Trucchio maintains $Silence Therapeutics(SLN.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate
Silence Therapeutics: Strong Buy on Underappreciated Blockbuster Potential and Clinical Advancements
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Morgan Stanley Reaffirms Their Buy Rating on Silence Therapeutics (SLN)
More Unpleasant Surprises Could Be In Store For Silence Therapeutics Plc's (NASDAQ:SLN) Shares After Tumbling 26%
Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations
Analyst Expectations For Silence Therapeutics's Future
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
BMO Capital analyst Kostas Biliouris maintains $Silence Therapeutics(SLN.US)$ with a buy rating, and maintains the target price at $67.According to TipRanks data, the analyst has a success rate of 44.
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target
Silence Therapeutics Reports Q2 Results
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
Chardan Capital analyst Keay Nakae maintains $Silence Therapeutics(SLN.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 38.5%